2. Search Result
Search Result
Results for "

cleavable site

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

5

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123740
    Disuccinimidyl sulfoxide

    DSSO

    		 Biochemical Assay Reagents Others
    Disuccinimidyl sulfoxide (DSSO) is a mass spectrometry (MS)-cleavable cross-linker that is applicable for model peptides and proteins and a multisubunit protein complex. Disuccinimidyl sulfoxide contains two symmetric collision-induced dissociation (CID)-cleavable sites for identification of DSSO-cross-linked peptides based their distinct fragmentation patterns .
    Disuccinimidyl sulfoxide
  • HY-112157
    PF-06751979
    1 Publications Verification

    		 Beta-secretase Neurological Disease
    PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 7.3 nM in BACE1 binding assay.
    PF-06751979
  • HY-N1255
    Scoulerine

    (-)-Scoulerine; Discretamine

    		 Microtubule/Tubulin Beta-secretase Apoptosis Cancer
    Scoulerine ((-)-Scoulerine), an isoquinoline alkaloid, is a potent antimitotic compound. Scoulerine is also an inhibitor of BACE1 (?-site amyloid precursor protein cleaving enzyme 1). Scoulerine inhibits proliferation, arrests cell cycle, and induces apoptosis in cancer cells .
    Scoulerine
  • HY-146125
    CGCG/CGG ligand 1

    		Endonuclease Metabolic Disease
    CGCG/CGG ligand 1 (compound 10), an anthracenone derivative, is a CGCG or CGG short spacer-ligand. CGCG/CGG ligand 1 can protect cleavable sites of DNA with the multiple CGCG or continuous CGG sites from the restriction enzyme .
    CGCG/CGG ligand 1
  • HY-P2610
    Ac-VEID-pNA

    		Caspase Others
    Ac-VEID-pNA is an artificially synthesized peptide. Ac-VEID-pNA is utilized as substrate for caspase 6, that cleaves the lamin A at the cleavage site of VEID .
    Ac-VEID-pNA
  • HY-144739
    BACE1-IN-8

    		Beta-secretase Neurological Disease
    BACE1-IN-8 (compound 70b) is a potent BACE1 (β-site APP cleaving enzyme 1) inhibitor, with an IC50 of 3.9 µM .
    BACE1-IN-8
  • HY-144741
    BACE1-IN-9

    		Beta-secretase Neurological Disease
    BACE1-IN-9 (compound 82b) is a potent BACE1 (β-site APP cleaving enzyme 1) inhibitor, with an IC50 of 1.2 µM .
    BACE1-IN-9
  • HY-E70128
    Leucyl aminopeptidase

    		Others Others
    Leucyl aminopeptidase is a metallopeptidase that cleave N-terminal residues from proteins and peptides. Leucyl aminopeptidase serves as transcriptional repressors to control pyrimidine, alginate and cholera toxin biosynthesis, as well as mediate site-specific recombination events in plasmids and phages .
    Leucyl aminopeptidase
  • HY-E70393J
    Bovine Factor XIa

    		Others Others
    Bovine Factor XIa is an enzyme, which is involved in the intrinsic pathway of blood coagulation. Bovine Factor XIa is highly selective and exhibits a minimal extended substrate recognition site of at least five residues long. Bovine Factor XIa is reactive as Bovine Factor IXa (HY-E70393I) does, that it cleaves all the peptides bearing factor IX activation site sequences .
    Bovine Factor XIa
  • HY-108966
    Kushenol C

    		Beta-secretase Inflammation/Immunology
    Kushenol C, isolated from the roots of Sophora flavescens, shows anti-Inflammatory and anti-oxidative stress activities. Kushenol C inhibits BACE1 (β-site APP cleaving enzyme 1) with an IC50 of 5.45 µM .
    Kushenol C
  • HY-P99238
    Rolinsatamab

    		ADC Antibody Inflammation/Immunology Cancer
    Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .
    Rolinsatamab
  • HY-U00287
    BACE-IN-1

    		Beta-secretase Neurological Disease
    BACE-IN-1 (Compound 13) is a substituted lmidazo[1 ,2-a]pyridine derivative which can inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease.
    BACE-IN-1
  • HY-145657
    Benzoquinoquinoxaline

    BQQ

    		 Others Others
    Benzoquinoquinoxaline (BQQ) is a heterocyclic compound with an aminoalkyl side chain. Benzoquinoquinoxaline preferentially binds to DNA triplex structures, intercalates between the bases, thus, stabilising the triplex conformation. Conjugation of Benzoquinoquinoxaline to 1,10-phenanthroline specifically binds and cleaves double strand DNA at the site of formation of a triplex structure .
    Benzoquinoquinoxaline
  • HY-119689
    Umibecestat

    CNP520

    		 Beta-secretase Neurological Disease
    Umibecestat (CNP520) is a beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) inhibitor with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively . Umibecestat can be used for the research of alzheimer's disease.
    Umibecestat
  • HY-15908
    BCA
    5 Publications Verification

    Disodium bicinchoninate

    		 Beta-secretase Neurological Disease Cancer
    BCA (Disodium bicinchoninate) is an orally active and non-competitive Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 value of 28 µM, a Ki value of 43 µM. BCA shows anticancer activity. BCA has the potential for the research of Alzheimer's disease (AD) .
    BCA
  • HY-109052
    Atabecestat

    JNJ-54861911

    		 Beta-secretase Neurological Disease
    Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .
    Atabecestat
  • HY-130244
    BACE1-IN-5

    		Beta-secretase Neurological Disease
    BACE1-IN-5 (Compound 15) is a β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 9.1 nM, and also inhibits cellular amyloid-β (Aβ) with an IC50 of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux .
    BACE1-IN-5
  • HY-P10668
    Ac-EVKKQR-pNA

    		Dengue virus Flavivirus Infection
    Ac-EVKKQR-pNA is a competitive chromogenic para-nitroanilide substrate corresponding to the P6-P1 segment amino-terminal to the NS2B-NS3 cleavage site but with a more reactive, hydrolytically cleavable, para-nitroanilide at the P1’ position. Ac-EVKKQR-pNA is promising for research of dengue 2 virus and flavivirus virus infection .
    Ac-EVKKQR-pNA
  • HY-130426
    Maleimido-tri(ethylene glycol)-propionic acid

    Mal-PEG3-acid

    		 ADC Linker PROTAC Linkers Cancer
    Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-specific cysteine mutant trastuzumab-A114C conjugation . Maleimido-tri(ethylene glycol)-propionic acid also can be used as a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    Maleimido-tri(ethylene glycol)-propionic acid
  • HY-13240
    LY2886721
    2 Publications Verification

    		 Beta-secretase Neurological Disease
    LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
    LY2886721
  • HY-13240A
    LY2886721 hydrochloride

    		Beta-secretase Neurological Disease
    LY2886721 hydrochloride is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
    LY2886721 hydrochloride
  • HY-128774
    AM-6494

    		Beta-secretase Neurological Disease
    AM-6494 is a potent and orally active BACE1 (efficacious β-site amyloid precursor protein cleaving enzyme 1) inhibitor (IC50=0.4 nM) with in vivo selectivity over BACE2 (IC50=18.6 nM) . AM-6494 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AM-6494
  • HY-P5272
    Histatin-3 TFA

    		Bacterial Inflammation/Immunology
    Histatin-3 TFA, a 32 amino acid peptide, possesses powerful antimicrobial properties. Histatin-3 TFA behaves as a substrate for proprotein convertase 1 (PC1), being cleaved by this endoprotease primarily at a site carboxy terminal to the single Arg25 residue (HRGYR decrease SN). Histatin-3 TFA is a moderately potent, reversible and competitive inhibitor of the furin-mediated cleavage of the pentapeptide pGlu-Arg-Thr-Lys-Arg-MCA fluorogenic substrate, with an estimated inhibition constant Ki of 1.98 μM .
    Histatin-3 TFA
  • HY-D2449
    DQ-BSA-RED

    		Fluorescent Dye Others
    DQ-BSA-Red is a bovine serum albumin labeled with a red fluorescent dye that can be used to detect lysosomal activity. The excitation wavelength and emission wavelength of DQ-BSA-Red are 590 nm and 620 nm, respectively. The BSA molecule in DQ-BSA-Red is labeled with high concentration of red fluorescent dye in multiple sites, which shows high fluorescence self-inhibition. Once DQ-BSA-RED enters the lysosome, DQ-BSA is cleaved by lysosomal proteases, resulting in unquenched and released fluorescent fragments, emitting bright fluorescence. Inactivated lysosomes are unable to degrade the BSA protein and thus have a lower or even no fluorescent signal .
    DQ-BSA-RED
  • HY-P5415
    DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS

    		HIV Others
    DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is a biological active peptide. (DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is also called HIV protease substrate I in some literature. It is widely used for the continuous assay for HIV protease activity. The 11-kD protease (PR) encoded by the human immunodeficiency virus 1 (HIV-1) is essential for the correct processing of viral polyproteins and the maturation of infectious virus, and is therefore a target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. The FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of recombinant HIV-1 PR with the fluorogenic substrate resulted in specific cleavage at the Tyr-Pro bond and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. The fluorescence quantum yields of the HIV-1 PR substrate in the FRET assay increased by 40.0- and 34.4-fold, respectively, per mole of substrate cleaved. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this substrate offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs. Abs/Em = 340nm/490nm.)
    DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: